Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.12 +0.92 (+2.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
From Exelixis, Inc.
Via Business Wire
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock. 
Via The Motley Fool
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive. 
Via Chartmill
14 Analysts Have This to Say About Exelixis
Via Benzinga
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility. 
Via InvestorPlace
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool
The Latest Analyst Ratings for Exelixis
Via Benzinga
Where Exelixis Stands With Analysts
Via Benzinga
Analyst Expectations for Exelixis's Future
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023
Via Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule... 
Via Talk Markets
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
From Exelixis
Via Business Wire
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
Exelixis Inc. (NASDAQ: EXEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the... 
Via Benzinga
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
2 No-Brainer Biotech Stocks to Buy Right Now
These two companies make a compelling case for a high price. 
Via The Motley Fool
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. 
Via InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.